How much funding has Pepromene raised?

Pepromene has raised $11.0M in total funding, most recently a Grant round.

Where is Pepromene headquartered?

Pepromene is headquartered in Irvine, California, United States.

What industry is Pepromene in?

Pepromene operates in Biotech, Healthcare.

Pepromene

Q: Who are Pepromene's investors?

Pepromene's investors include Institute for Follicular Lymphoma Innovation, KB Investment.

Irvine, United States · $11.0M raised

Biotech

Healthcare

Headquarters: Irvine, California
Employees: 1–10
Business Model: B2B
Website: pepromenebio.com

Total Funding: $11.0M
Last Round: $11.0M GrantDec 2024
Rounds: 2

About

PeproMene Bio, Inc. is a clinical-stage biotechnology company based in Irvine, California, committed to developing novel immune therapies to treat cancers and immune disorders. The company's lead program is its BAFF-R CAR-T therapy, based on a novel antibody targeting the B-cell Activating Factor Receptor (BAFF-R) discovered by Dr. Larry Kwak's team at MD Anderson Cancer Center and City of Hope National Medical Center. BAFF-R is an excellent target for B-cell cancers due to its specificity and expression levels in lymphoproliferative and leukemia-proliferative disorders. PeproMene Bio's pipeline includes PMB-101 for relapsed/refractory B-cell acute lymphoblastic leukemia and PMB-102 for relapsed/refractory mantle cell lymphoma, with additional programs targeting B-cell malignancies and autoimmune disorders. The company's BAFFR-CAR T cell therapy has demonstrated polyfunctionality and durable responses in clinical settings, including efficacy after prior CD19 CAR-T cell failure, and received an oral presentation at EHA 2026.

Summary

Pepromene is a Biotech company based in Irvine, United States. It has raised $11.0M in total across 2 rounds, most recently a $11.0M Grant round in Dec 2024. Investors include Institute for Follicular Lymphoma Innovation and KB Investment.